Entity
Description
  • Value proposition

    Acoustic Cell Processing Solution

    🚀 Aenitis designs, develops, and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing better, safer, and less expensive. By precisely controlling levitated cells with sound waves, our systems handle cells in full sterile conditions and radically increase productivity while preserving the native state of cells at every step of the engineering process. This technology enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing for the handling of tens of milliliters per minute. Such capabilities are critical for scaling applications from research to clinical and industrial use.
    đź’ˇToday, we have achieved proof-of-concepts for our contact-free & label-free proprietary technology across multiple cell types & processes. MitisTM, our flagship product, is already used for a wide range of applications, including cell sorting, isolation, concentration & washing, from research to clinical and industrial scale.
    🌍Co-founded by pioneers of acoustic levitation & fluid mechanics and a biotech entrepreneur, the company benefits from the support of the European Commission & the French Government and from the commitment of leading investors, notably the European Investment Bank and Seventure Partners.

    Sorting, acoustophoresis, medical devices, cells, and Bioproduction

  • Original language

    Acoustic Cell Processing Solution

    🚀 Aenitis designs, develops, and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing better, safer, and less expensive. By precisely controlling levitated cells with sound waves, our systems handle cells in full sterile conditions and radically increase productivity while preserving the native state of cells at every step of the engineering process. This technology enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing for the handling of tens of milliliters per minute. Such capabilities are critical for scaling applications from research to clinical and industrial use.
    đź’ˇToday, we have achieved proof-of-concepts for our contact-free & label-free proprietary technology across multiple cell types & processes. MitisTM, our flagship product, is already used for a wide range of applications, including cell sorting, isolation, concentration & washing, from research to clinical and industrial scale.
    🌍Co-founded by pioneers of acoustic levitation & fluid mechanics and a biotech entrepreneur, the company benefits from the support of the European Commission & the French Government and from the commitment of leading investors, notably the European Investment Bank and Seventure Partners.

Catalyst interactions
Catalyst TypeTweets Articles
MOVE: Mobility Re-imagined MOVE: Mobility Re-imagined
Other
ANSSI - Agence nationale de la sécurité des systèmes d'information ANSSI - Agence nationale de la sécurité des systèmes d'information
Other

11 Apr 2025


Ministère des Affaires étrangères français Ministère des Affaires étrangères français
Other

11 Apr 2025


Ministère de la Culture Ministère de la Culture
Other

11 Apr 2025


Ministère de la Défense Ministère de la Défense
Other

11 Apr 2025


Ministère de l'Agriculture et de la Souveraineté alimentaire Ministère de l'Agriculture et de la Souveraineté alimentaire
Government Administration
Other

11 Apr 2025


ADEME
ADEME
National and local authorities, Environmental Services
ADEME
National and local authorities, Environmental Services
Other

11 Apr 2025


Direction Générale des Entreprises
Direction Générale des Entreprises
National and local authorities, Government Administration
Direction Générale des Entreprises
National and local authorities, Government Administration
Other

11 Apr 2025


Groupe Caisse des Dépôts
Groupe Caisse des Dépôts
Finance, Government Administration
Groupe Caisse des Dépôts
Finance, Government Administration
Other

11 Apr 2025


J.P. Morgan J.P. Morgan
Bank
Other

16 Jan 2025


Social network dynamics
Similar entities
BETA
Loading...
Loading...